New cell therapy shows promise for tough blood cancer
Disease control
Terminated
This early-stage trial tested a new treatment for acute myeloid leukemia (AML), a blood cancer that had come back or not responded to standard care. The therapy uses a patient's own immune cells, modified to recognize and attack cancer cells carrying a specific marker (CD123). Th…
Phase: PHASE1 • Sponsor: AvenCell Europe GmbH • Aim: Disease control
Last updated May 26, 2026 12:09 UTC